dry eye disease

Can cannabis succeed where other compounds have failedUse of a novel semi-fluorinated alkane drug delivery technology as a vehicle to deliver cannabinoids to the ocular surface reached target tissues without systemic side effects in preclinical studies.
Intranasal neurostimulator shows benefit for increasing tear productionResults from two pivotal multicenter trials demonstrate that an intranasal tear neurostimulator (TrueTear, Allergan) safely and effectively increases endogenous tear production in patients with dry eye disease (DED), said Edward Holland, MD.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Using neurostimulation to treat dry eye
Using neurostimulation to treat dry eyeNeurostimulation could be the “next big thing” in dry eye disease (DED). A new neurostimulation device called TrueTear (Allergan) is a patient-directed, non-pharmacologic option.
5 things you need to know about TFOS DEWS IIWith great anticipation, the updated report of the TFOS Dry Eye WorkShop (DEWS II) was released last week. The first DEWS report was released in 2007.
Dry eye checklist may help ODs treat patients more efficiently
Dry eye checklist may help ODs treat patients more efficientlyScott Schachter, OD, discusses dry eye and how incorporating a dry eye checklist may help improve patient treatment.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
First patients enrolled in dry eye device studyPatient recruitment has started in a randomised clinical trial testing an experimental device (Lamelleye, known also as CXB/1-14) for the treatment of dry eye disease (DED).
Understanding the role of inflammation in dry eye
Understanding the role of inflammation in dry eyeOptometry Times Editorial Advisory Board members Leslie E. O’Dell. OD, FAAO, and Scott Hauswirth, OD, FAAO, discuss their recent lecture on inflammation and the role it plays in ocular surface diseases at the American Optometric Association’s Optometry’s Meeting in Washington, DC.